Tirzepatide (HA) 10mg
Tirzepatide is a synthetic compound derived from gastric inhibitory polypeptide (GIP), with the added functionality of glucagon-like peptide-1 (GLP-1). By combining these properties, Tirzepatide effectively reduces blood glucose levels, improves insulin sensitivity, enhances satiety, and promotes weight loss. While originally developed as a treatment for type 2 diabetes, Tirzepatide has also demonstrated the ability to protect the cardiovascular system and act as a potent agent for weight reduction.
Buy 3 and get 3% off – Buy 5 and get 5% off – Buy 10 and get 10% off
**This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This classification permits the only use of research chemicals for in vitro testing and laboratory research. This website only provides product information for educational purposes. It is illegal to introduce any form of bodily material into either people or animals. Only professionals with the appropriate training and licences should handle this product. This product may not be misbranded, used improperly, or labelled as a medication, food, or cosmetic because it is not one of those things.
Description:
Tirzepatide belongs to a class of medications called glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucagon receptor agonist (GRA) dual agonists.
Tirzepatide is being developed for the treatment of type 2 diabetes mellitus. GLP-1 RA drugs work by increasing the secretion of insulin, which helps lower blood sugar levels, and by reducing the production of glucagon, which helps prevent the liver from releasing excess glucose into the bloodstream. GRA drugs, on the other hand, work by decreasing the levels of glucagon, which can help reduce blood sugar levels.
The combination of GLP-1 RA and GRA properties in tirzepatide aims to provide more effective blood sugar control compared to individual medications. It is also believed to promote weight loss and may have additional benefits such as cardiovascular risk reduction.
Tirzepatide (HA) Research:
There are several clinical trials evaluating the efficacy and safety of tirzepatide. Here are some key findings from the available research:
- SURPASS-1 and SURPASS-2 Trials: These Phase 3 trials evaluated the use of tirzepatide in patients with type 2 diabetes. The studies compared tirzepatide with placebo and other standard treatments, such as insulin glargine and dulaglutide. The results showed that tirzepatide significantly reduced HbA1c levels (a measure of long-term blood glucose control) and body weight compared to the comparator treatments.
- SURMOUNT-1 Trial: This Phase 3 trial investigated the use of tirzepatide in patients with obesity. The study compared tirzepatide with placebo and liraglutide, another GLP-1 receptor agonist. The findings indicated that tirzepatide led to greater weight loss compared to placebo and similar weight loss compared to liraglutide.
- Cardiometabolic Effects of Tirzepatide: Several studies have examined the cardiometabolic effects of tirzepatide. These studies have shown that tirzepatide can improve cardiovascular risk factors, including reducing blood pressure and improving lipid profiles. Furthermore, tirzepatide has demonstrated potential benefits for cardiovascular outcomes, such as reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease.
Related products
Original price was: CAD$65.00.CAD$60.00Current price is: CAD$60.00.
Original price was: CAD$85.00.CAD$75.00Current price is: CAD$75.00.
Original price was: CAD$70.00.CAD$60.00Current price is: CAD$60.00.
CAD$65.00
